Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir-HU add-on therapy in asymptomatic to mild COVID-19
2020-006042-39Phase 2Terminated
- Sponsor
- Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of favipiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium. Primary endpoint: Primary: Percentage of virus copy number at Day 6 compared to baseline. Started Jan 2021; status: terminated.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-006042-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006042-39.